178 related articles for article (PubMed ID: 15675090)
1. Caspofungin versus liposomal amphotericin B for empirical therapy.
Jones BL; McLintock LA
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675090
[No Abstract] [Full Text] [Related]
2. Caspofungin versus liposomal amphotericin B for empirical therapy.
Tattevin P; Bareau B; Camus C
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
[No Abstract] [Full Text] [Related]
3. Caspofungin versus liposomal amphotericin B for empirical therapy.
Schneemann M; Imhof A
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094
[No Abstract] [Full Text] [Related]
4. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
5. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
6. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin versus liposomal amphotericin B for empirical therapy.
Marty FM; Lowry CM
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675093
[No Abstract] [Full Text] [Related]
8. Caspofungin versus liposomal amphotericin B for empirical therapy.
Kontoyiannis DP; Lewis RE
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15673808
[No Abstract] [Full Text] [Related]
9. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
Klastersky J
N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
[No Abstract] [Full Text] [Related]
10. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
de Pauw BE; Sable CA; Walsh TJ; Lupinacci RJ; Bourque MR; Wise BA; Nguyen BY; DiNubile MJ; Teppler H
Transpl Infect Dis; 2006 Mar; 8(1):31-7. PubMed ID: 16623818
[TBL] [Abstract][Full Text] [Related]
11. New type of effective antifungal treatment identified.
Bosch X
Lancet Oncol; 2004 Nov; 5(11):645. PubMed ID: 15536684
[No Abstract] [Full Text] [Related]
12. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B.
Bassetti M; Bisio F; Di Biagio A; Pierri I; Balocco M; Soro O; Cruciani M; Bassetti D
J Antimicrob Chemother; 2004 Aug; 54(2):575-7. PubMed ID: 15231763
[No Abstract] [Full Text] [Related]
13. [Caspofungin in the replacement of amphotericin B in the treatment of fungal diseases].
Yang W; He B
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):53. PubMed ID: 15808079
[No Abstract] [Full Text] [Related]
14. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia.
Makowsky MJ; Warkentin DI; Savoie ML
Ann Pharmacother; 2005; 39(7-8):1365-6. PubMed ID: 15956243
[No Abstract] [Full Text] [Related]
16. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
17. Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation.
Pancham S; Hemmaway C; New H; Albert E; Dokal I; Roberts IA; McCloy M
Pediatr Transplant; 2005 Apr; 9(2):254-7. PubMed ID: 15787803
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin versus liposomal amphotericin B: are they really comparable?
Sekine L; Humbwavali J; Wolff FH; Barcellos NT
Pediatr Infect Dis J; 2010 Oct; 29(10):985-6; author reply 986-7. PubMed ID: 20859182
[No Abstract] [Full Text] [Related]
19. Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.
Bocanegra R; Najvar LK; Hernandez S; McCarthy DI; Graybill JR
Antimicrob Agents Chemother; 2005 Dec; 49(12):5139-41. PubMed ID: 16304187
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
Wingard JR; Leather HL; Wood CA; Gerth WC; Lupinacci RJ; Berger ML; Mansley EC
Am J Health Syst Pharm; 2007 Mar; 64(6):637-43. PubMed ID: 17353573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
